Alexion Pharmaceuticals is aligning itself with biotech Blueprint Medicines, borrowing the company’s drug development technology to spotlight new treatments for genetic disorders. Under a pending deal, Alexion will pay $15 million up front for the rights to an untold number of drug candidates with potential in treating an undisclosed rare disease. Alexion is on the line to reimburse all of Blueprint’s research expenses as the company handles discovery and preclinical research, promising as much as $250 million more tied to developmental milestones.

“Blueprint Medicines’ unique discovery platform enables it to create drug candidates for extremely challenging kinase targets,” Alexion R&D chief Martin Mackay said in a statement. “Even in these early stages, Blueprint Medicines’ compounds show impressive selectivity toward the mutant kinase, thereby sparing other kinases and delivering drug to the specified target.”

Separately, Alexion announced that the FDA has accepted for Priority Review the Company’s Biologics License Application for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for treatment of patients with infantile- and juvenile-onset hypophosphatasia) … more